A Study to Evaluate Single Doses of Alpha-0261 in Healthy Adult Volunteers

A Randomized, Double-blind, Placebo-Controlled, Dose-Escalation, Phase Ia Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Oral Administration of Alpha-0261 Tablets in Adult Healthy Participants

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of Alpha-0261 tablets after single oral administration in healthy adult volunteers.

Inclusion Criteria:

• Aged ≥ 18 and ≤ 55, male or female
• Weight: ≥ 50 kg for males, ≥ 45 kg for females; 19 kg/m2 ≤ body mass index (BMI) ≤ 28 kg/m2
• In general good health

Exclusion Criteria:

• Have a history of any severe allergic reaction or anaphylaxis
• Any condition, which in the investigator's opinion might jeopardize participant's safety or compliance with the protocol
• Have clinically significant abnormalities on clinical laboratory results